Compare PVLA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVLA | VCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2013 | 1996 |
| Metric | PVLA | VCEL |
|---|---|---|
| Price | $151.21 | $39.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $171.87 | $57.75 |
| AVG Volume (30 Days) | 160.3K | ★ 455.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.62 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | $42,810,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $104,350.18 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.28 | 16.45 |
| 52 Week Low | $56.55 | $28.95 |
| 52 Week High | $161.38 | $49.32 |
| Indicator | PVLA | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 42.13 |
| Support Level | $145.91 | $35.32 |
| Resistance Level | $151.18 | $41.25 |
| Average True Range (ATR) | 5.61 | 1.23 |
| MACD | -0.27 | 0.15 |
| Stochastic Oscillator | 51.04 | 60.63 |
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.